| ORIGINAL ARTICLE |
|
| Year : 2022 | Volume
: 18
| Issue : 78 | Page : 286-295 |
|
|
Xylocarpus moluccensis fruit fraction rescues cardiac hypertrophy by improving angiogenesis and regulating NF-κB-mediated inflammation
Amit Manhas1, Dipika Goyal2, Bharti Biswas2, Dipti Tripathi1, Pragya Yadav3, Abhinav Singh1, Shri Krishna2, Narender Tadigoppula3, Madhu Dikshit1, Kumaravelu Jagavelu1
1 Department of Pharmacology, CSIR-Central Drug Research Institute, Lucknow; Academy of Science and Innovation Research, New Delhi, India
2 Department of Pharmacology, CSIR-Central Drug Research Institute, Lucknow, India
3 Academy of Science and Innovation Research, New Delhi; Medicinal and Process Chemistry, CSIR-Central Drug Research Institute, Lucknow, India
Correspondence Address:
Kumaravelu Jagavelu
Principal Scientist, Pharmacology Division, CSIR-Central Drug Research Institute, CDRI/B.S.10/1, Sector 10, Jankipuram Extension, Sitapur Road, Lucknow-226031
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/pm.pm_79_21
|
|
|
Background and Aim: The present study was undertaken to investigate the potential of ethyl acetate fraction obtained from the fruits of Xylocarpus moluccensis alcoholic extract (CDR-267-F018) against cardiac hypertrophy in rats. Experimental Procedure: Cardiac hypertrophy was achieved in Wistar rats through isoproterenol and treated either with propranolol or CDR-267-F018 for 14 days. Results and Conclusion: CDR-267-F018 treatment reduced isoproterenol induced cardiac hypertrophy as assessed by 2D-echocardiography and supported by reduction in ANP, BNP, β-MHC, NPP-A and increased expression of vascular endothelial growth factor receptor 1. CDR-267-F018 treatment tightly regulated inflammation by controlling the plasma proinflammatory cytokines tumor necrosis factor-α and IFN-γ, plasma EMP level and NF-κB, Akt and ERK. Further, CDR-267-F018 treatment reduced fibrosis by regulating Col18a1, FGF-21 and MMP2. In total, CDR-267-F018 protected rat heart against isoproterenol induced cardiac hypertrophy by acting on inflammation, fibrosis and by improving angiogenesis.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
